118 related articles for article (PubMed ID: 12870689)
1. Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy.
Santin M; Alcaide F
Int J Tuberc Lung Dis; 2003 Jul; 7(7):673-7. PubMed ID: 12870689
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects.
Tompkins JC; Witzig RS
Int J Tuberc Lung Dis; 2007 Mar; 11(3):331-7. PubMed ID: 17352101
[TBL] [Abstract][Full Text] [Related]
3. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
[TBL] [Abstract][Full Text] [Related]
4. [Ocular manifestations in patients with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy].
Mesarić B; Lisić M; Kniewald T; Ugrinović N; Begovac J
Lijec Vjesn; 2005; 127(5-6):123-8. PubMed ID: 16281473
[TBL] [Abstract][Full Text] [Related]
5. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
6. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
[TBL] [Abstract][Full Text] [Related]
7. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
8. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study.
Canueto-Quintero J; Caballero-Granado FJ; Herrero-Romero M; Domínguez-Castellano A; Martín-Rico P; Verdú EV; Santamaría DS; Cerquera RC; Torres-Tortosa M;
Clin Infect Dis; 2003 Aug; 37(4):584-90. PubMed ID: 12905144
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit.
Palacios R; Hidalgo A; Reina C; de la Torre M; Márquez M; Santos J
HIV Med; 2006 Apr; 7(3):193-6. PubMed ID: 16494634
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
12. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus.
Marras TK; Morris A; Gonzalez LC; Daley CL
Am J Respir Crit Care Med; 2004 Oct; 170(7):793-8. PubMed ID: 15215152
[TBL] [Abstract][Full Text] [Related]
13. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
15. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
[TBL] [Abstract][Full Text] [Related]
16. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
Choi AI; Rodriguez RA; Bacchetti P; Volberding PA; Havlir D; Bertenthal D; Bostrom A; O'Hare AM
Clin Infect Dis; 2007 Dec; 45(12):1633-9. PubMed ID: 18190326
[TBL] [Abstract][Full Text] [Related]
17. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
18. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
[TBL] [Abstract][Full Text] [Related]
19. Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan.
Hung CC; Hsiao CF; Chen MY; Hsieh SM; Chang SY; Sheng WH; Sun HY; Chang SC
Jpn J Infect Dis; 2006 Aug; 59(4):222-8. PubMed ID: 16936339
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1-related pulmonary Mycobacterium xenopi infection: a need to treat?
Kerbiriou L; Ustianowski A; Johnson MA; Gillespie SH; Miller RF; Lipman MC
Clin Infect Dis; 2003 Nov; 37(9):1250-4. PubMed ID: 14557971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
